NCT06763640 is a clinical trial in Nasopharyngeal Carcinoma (NPC), sponsored by Jiangxi Provincial Cancer Hospital.

Who is sponsoring NCT06763640?

NCT06763640 is sponsored by Jiangxi Provincial Cancer Hospital.

What condition does NCT06763640 study?

NCT06763640 studies Nasopharyngeal Carcinoma (NPC).

Is NCT06763640 still recruiting?

NCT06763640 is currently enrolling by invitation. Last updated 9 January 2025.

Last reviewed 2025-01-09 · How we verify

NCT06763640

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Value of TIL in Nasopharyngeal Carcinoma

ENROLLING BY INVITATION Last updated 9 January 2025

What this trial tests

trial in Nasopharyngeal Carcinoma (NPC) in 216 participants. Enrolling by invitation.

Timeline

1 January 2025

Primary endpoint
31 December 2027

31 December 2028

Quick facts

Lead sponsor	Jiangxi Provincial Cancer Hospital
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	216
Start date	1 January 2025
Primary completion	31 December 2027
Estimated completion	31 December 2028
Sites	1 location across China

Conditions studied

Nasopharyngeal Carcinoma (NPC) — all drugs for Nasopharyngeal Carcinoma (NPC) →

Sponsor

Jiangxi Provincial Cancer Hospital

Who can join

Adults 18 to 70, any sex, with Nasopharyngeal Carcinoma (NPC). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our center plans to conduct a prospective, multicenter, observational study aimed at observing the percentage of TIL infiltration calculated using deep learning methods based on digital pathological images, and analyzing its prognostic significance in nasopharyngeal carcinoma, in order to help guide personalized treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates.
Kim J, Kim HS, Nam M, Chae YK. · · 2025 · cited 3× · PMID 40576713 · DOI 10.1007/s10555-025-10274-2
Response to correspondence on 'Deep learning-based quantification of tumor-infiltrating lymphocytes as a prognostic indicator in nasopharyngeal carcinoma: multicohort findings'.
Lu T, Li J. · · 2025 · PMID 41223632 · DOI 10.1016/j.esmoop.2025.105881

Verify or expand the search:

Other recruiting trials for Nasopharyngeal Carcinoma (NPC)

Currently open trials in the same condition.

NCT07459296 — Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC · Phase 3 · recruiting
NCT06796270 — Hypofractionated Radiotherapy for Nasopharyngeal Carcinoma · NA · recruiting
NCT07340515 — Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial · Phase 3 · recruiting
NCT07328841 — Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinom · Phase 3 · recruiting
NCT07101744 — Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure · Phase 2 · recruiting

Other Jiangxi Provincial Cancer Hospital trials

Trials by the same sponsor.

NCT07314255 — The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma · active not recruiting
NCT07277764 — Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carc · Phase 2 · recruiting
NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting
NCT07085988 — Effect of Nutritional Management on Patients With Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma · Phase 2 · recruiting
NCT06770699 — Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06763640 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangxi Provincial Cancer Hospital
Last refreshed: 9 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06763640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing